Safety and Efficacy Study of AC-3933 in Adults With Mild to Moderate Alzheimer's Disease
NCT ID: NCT00359944
Last Updated: 2013-07-02
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
171 participants
INTERVENTIONAL
2006-02-28
2008-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Safety, Tolerability, and Blood Levels of ACU193 in Participants With MCI or Mild AD
NCT04931459
A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease
NCT00930059
A Phase I, Single Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease
NCT00607308
A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's Disease
NCT03019536
Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease
NCT03703856
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AC-3933
AC-3933, 5mg twice daily
AC-3933
5mg twice daily
AC-3933, 20 mg twice daily
AC-3933, 20 mg twice daily
AC-3933
AC-3933, 20 mg twice daily
Placebo
Sugar Pill twice daily
Sugar Pill
Sugar Pill twice daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AC-3933
5mg twice daily
AC-3933
AC-3933, 20 mg twice daily
Sugar Pill
Sugar Pill twice daily
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male or female 55 years or older
* Living with caregiver
* Read, understand and speak English
Exclusion Criteria
* Treatment with acetylcholinesterase inhibitors or NMDA antagonist, such as Aricept or Namenda, within 2 weeks of check-up and during the study
* Frequent Smoker
* Frequent Consumer of Caffeine
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sumitomo Pharma America, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director, MD
Role: STUDY_DIRECTOR
Sumitomo Pharma America, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Trials Inc.
LIttle Rock, Alaska, United States
PsyPharma Clinical Research Inc.
Phoenix, Arizona, United States
ClinicalStudies Center LLC
Little Rock, Arkansas, United States
Vertex Clinical Research
Bakersfield, California, United States
East Bay Physicians Medical Grou[
Berkeley, California, United States
Margolin Brain Institute
Fresno, California, United States
Clinical Trials Associates
Mission Viejo, California, United States
University of California
Orange, California, United States
Pacific Research Network
San Diego, California, United States
Memory Disorder Clinic
Deerfield Beach, Florida, United States
Berma Research Group
Hialeah, Florida, United States
Advanced Research Institute of Miami
Miami, Florida, United States
Research Institute of Miami
Miami, Florida, United States
Research Center of Florida Inc.
Miami, Florida, United States
Medical Research Group of Central Florida
Orange City, Florida, United States
Compass Research LLC
Orlando, Florida, United States
Department of Psychiatry and Behavioral Medicine
Tampa, Florida, United States
Stedman Clinical Trials LLC
Tampa, Florida, United States
Four Rivers Clinical Research Inc.
Paducah, Kentucky, United States
Northern Michigan Neurology
Traverse City, Michigan, United States
Minneapolis, Minnesota, United States
Clinical Psychopharmacology Consultants PA
Saint Louis Park, Minnesota, United States
Precise Research Centers INc.
Flowood, Mississippi, United States
Psych Care Consultants Research
St Louis, Missouri, United States
Odyssey Researcfh
Fargo, North Dakota, United States
Paradigm Research Professionals LLP
Oklahoma City, Oklahoma, United States
Cutting Edge Research Group
Oklahoma City, Oklahoma, United States
Tulsa Clinical Research LLC
Tulsa, Oklahoma, United States
The Clinical Trial Center
Jenkintown, Pennsylvania, United States
UT Medical Group Inc.
Memphis, Tennessee, United States
Neurological Research Center, Inc.
Bennington, Vermont, United States
International Clinical Research Associates LLC
Richmond, Virginia, United States
The Center for Excellence in Aging and Geriatric Health
Williamsburg, Virginia, United States
Internal Medicine Northwest
Tacoma, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AC-3933-271
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.